Back to search
FDAFDA · Food and drugs·Recall number D-0190-2025

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Published January 15, 2025 · Recall initiated: December 30, 2024

Summary

FDA records drug Class II recall D-0190-2025, published January 15, 2025 and initiated December 30, 2024. Recalling firm: Rising Pharma Holding, Inc.; Status: Ongoing; Reported quantity: 244,460 bottles; Lot: Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Rising Pharma Holding, Inc.
Distributor
Nationwide
Lot
Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ recalled?

Yes. FDA published recall D-0190-2025 on January 15, 2025. Reported hazard: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter